Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05359913 | Podcasting Cervical Cancer Prevention for AAW | unknown | N/A | 40 | University of HoustonOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT05355727 | PROSAIC-DS Study (PROState AI in Cancer - Decision Support)(PROSAIC-DS) | unknown | N/A | 1,040 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04300673 |
| Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients(DETECT) |
| unknown |
| Phase 1 / Phase 2 |
| 20 |
| Radboud University Medical CenterOTHER |
| 1 |
| Apr 29, 2022 |
| clinicaltrials |
| NCT05297162 | PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective Trial(PROSPET-BX) | unknown | N/A | 128 | Istituto Clinico HumanitasOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03961737 | Study of the Response to Irradiation on Prostatic Explants ex Vivo, as a Predictive Factor of the Clinical Response to Irradiation of Prostate Cancers(EXPLANT) | unknown | N/A | 92 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05314907 | Acceptability of Self-sampling for Cervical Cancer Screening | unknown | N/A | 1,614 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327621 | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05311579 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05319145 | PeRsonalizing the Approach to the Oncologic Frail Individual Through Tailored Assessment and Intervention (PROFIT Study)(PROFIT) | unknown | N/A | 268 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 2 | Apr 13, 2022 | clinicaltrials |
| NCT05310305 | PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer | unknown | — | 20 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05310383 | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | unknown | Phase 2 | 58 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05316376 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05309122 | Cervical Cancer Screening Strategies | unknown | — | 10,000 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310331 | Donafenib for Recurrent Cervical Cancer | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310344 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 50 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310357 | Chromosomal Instability in Ovarian Cancer | unknown | — | 300 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310370 | HRD and Resistance to PAPPi in EOC Patients | unknown | — | 400 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04773821 | Performance of Prostate MRI and Following Biopsy to Detect Prostate Cancer Recurrence After Focal Therapy(IRMProft) | unknown | N/A | 260 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05259540 | Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | unknown | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05290415 | Host DNA Methylation for Endometrial Cancer Screening | unknown | — | 10,000 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290428 | DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening | unknown | — | 459 | Peking Union Medical College HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290922 | DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening | unknown | — | 7,150 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | unknown | Phase 2 | 122 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT03238170 | MR-simulation in Radiotherapy for Prostate Cancer(FIMRA-P) | unknown | N/A | 40 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05286840 | 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer | unknown | Phase 1 / Phase 2 | 150 | Luke Nordquist, MDOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05212857 | Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05192694 | Evaluation of Fapi-pet in Prostate Cancer.(FAPIPETPCA) | unknown | N/A | 40 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05274867 | Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment(PROM-OSP) | unknown | — | 137 | The Christie NHS Foundation TrustOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | unknown | Phase 1 | 80 | Shenzhen Kangzhe Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03526510 | Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer | unknown | N/A | 178 | Dr. Patrick CheungOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05270720 | Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer | unknown | Phase 1 | 9 | West China Second University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03572621 | Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality(PRODUCAN) | unknown | N/A | 240 | Hospices Civils de LyonOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | unknown | Phase 1 | 9 | Peking University People's HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262608 | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation(PROspect) | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05255861 | An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy | unknown | — | 300 | Xin WuOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05248282 | Clinical Validation of the Prognostic Value of the PrTS on Prostate Cancer Patients | unknown | — | 150 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05236855 | Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening | unknown | — | 200 | IWK Health CentreOTHER | 0 | Feb 11, 2022 | clinicaltrials |
| NCT05224024 | Retzius-sparing Technique in Robotic-assisted Radical Prostatectomy | unknown | N/A | 80 | Ankara UniversityOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05210348 | Clinical Evaluation of Detection of High Risk HPV in Urine(Urine-hrHPV) | unknown | — | 1,000 | Peking University People's HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2022source: clinicaltrials